Full text is available at the source.
Abstract
Adults with serious mental illness, type 2 diabetes, and obesity may experience elevated cardiovascular risk.
- The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with potential cardiometabolic benefits.
- GLP-1RA use may be linked to lower risks of incident myocardial infarction.
- There is a possibility that GLP-1RAs could reduce the risk of heart failure.
- The association between GLP-1RA use and all-cause mortality is also under investigation.
Simplified